{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:15:10Z","timestamp":1786965310333,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["LH RO1 CA195727"],"award-info":[{"award-number":["LH RO1 CA195727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009455","name":"WVU","doi-asserted-by":"publisher","award":["P20 GM109098"],"award-info":[{"award-number":["P20 GM109098"]}],"id":[{"id":"10.13039\/100009455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P20 GM103434"],"award-info":[{"award-number":["P20 GM103434"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM104942"],"award-info":[{"award-number":["U54GM104942"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010311","name":"Core","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008308","name":"Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100008308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bmc.2019.02.016","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T18:37:32Z","timestamp":1549823852000},"page":"1479-1488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Karen E.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paratchata","family":"Batsomboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Eschrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Robart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory B.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Geldenhuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Hazlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.02.016_b0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/asheducation.V2000.1.147.147","article-title":"Multiple myeloma: new insights and therapeutic approaches, hematology","author":"Anderson","year":"2000","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bmc.2019.02.016_b0010","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.02.016_b0015","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2019.02.016_b0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bmc.2019.02.016_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bmc.2019.02.016_b0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bmc.2019.02.016_b0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1006\/scdb.1999.0319","article-title":"Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum","volume":"10","author":"Noiva","year":"1999","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.bmc.2019.02.016_b0040","article-title":"Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma","author":"Robinson","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bmc.2019.02.016_b0045","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-08-0035","article-title":"Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress","volume":"68","author":"Lovat","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.02.016_b0050","doi-asserted-by":"crossref","first-page":"20110403","DOI":"10.1098\/rstb.2011.0403","article-title":"Ero1-PDI interactions, the response to redox flux and the implications for disulfide bond formation in the mammalian endoplasmic reticulum","volume":"368","author":"Benham","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.bmc.2019.02.016_b0055","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1097-2765(02)00696-2","article-title":"The FAD- and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum","volume":"10","author":"Tu","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2019.02.016_b0060","doi-asserted-by":"crossref","first-page":"20993","DOI":"10.1074\/jbc.M110.126599","article-title":"A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity","volume":"285","author":"Blais","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.02.016_b0065","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1038\/emboj.2010.222","article-title":"Crystal structures of human Ero1alpha reveal the mechanisms of regulated and targeted oxidation of PDI","volume":"29","author":"Inaba","year":"2010","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2019.02.016_b0070","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1021\/ol502410x","article-title":"Identification, synthesis, and evaluation of new neuraminidase inhibitors","volume":"16","author":"Kumar","year":"2014","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2019.02.016_b0075","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1021\/ol101568d","article-title":"Transition-metal-free catalytic synthesis of 1,5-diaryl-1,2,3-triazoles","volume":"12","author":"Kwok","year":"2010","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2019.02.016_b0080","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.ejmech.2016.12.024","article-title":"Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans","volume":"126","author":"Krake","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.02.016_b0085","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2019.02.016_b0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbamcr.2007.12.011","article-title":"Ero1 and redox homeostasis in the endoplasmic reticulum","volume":"1783","author":"Sevier","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmc.2019.02.016_b0095","doi-asserted-by":"crossref","first-page":"W310","DOI":"10.1093\/nar\/gkl206","article-title":"GRAMM-X public web server for protein-protein docking","volume":"34","author":"Tovchigrechko","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2019.02.016_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23123194","article-title":"Pharmacological inhibition of LSD1 for cancer treatment","volume":"23","author":"Yang","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2019.02.016_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5483\/BMBRep.2017.50.8.107","article-title":"Emerging roles of protein disulfide isomerase in cancer","volume":"50","author":"Lee","year":"2017","journal-title":"BMB Rep"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618318856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618318856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:59:58Z","timestamp":1760835598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618318856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0968089618318856"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.02.016","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}